Welcome to our dedicated page for Kura Oncology SEC filings (Ticker: KURA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Kura Oncology, Inc. filings document a Nasdaq-listed biopharmaceutical company focused on precision medicines for cancer, including disclosures on KOMZIFTI™ (ziftomenib), acute myeloid leukemia programs, darlifarnib (KO-2806) and collaboration activity with Kyowa Kirin. Form 8-K reports cover financial results, FDA approval and product-launch disclosures, clinical program updates, milestone payments and other material events.
Governance filings include the company’s definitive proxy statement for annual meeting matters, director elections, auditor ratification and executive compensation. Other filings describe amendments to bylaws, the 2023 Inducement Option Plan, nonstatutory stock option grants and the company’s common stock listing on The Nasdaq Global Select Market.
Armistice Capital, LLC and Steven Boyd filed Amendment No. 5 to a Schedule 13G/A reporting shared beneficial ownership of 3,736,000 shares of Kura Oncology common stock, equal to 4.23% (03/31/2026). The filing states Armistice Capital is the investment manager of Armistice Capital Master Fund Ltd., the direct holder, and that the Master Fund disclaims beneficial ownership by reason of its Investment Management Agreement with Armistice Capital.
Kura Oncology reported first-quarter 2026 results showing its transition into a commercial-stage company. Total revenue reached $18.3 million, including $5.8 million in net product revenue from KOMZIFTI, its newly launched AML drug, and $12.5 million of collaboration revenue from the Kyowa Kirin partnership.
The company’s operating expenses rose with commercialization and late-stage development, driving a net loss of $73.3 million, or $0.83 per share. Research and development spending was $65.3 million and selling, general and administrative expenses were $31.6 million, reflecting expanding clinical programs and commercial infrastructure.
Kura ended March 31, 2026 with $580.8 million in cash, cash equivalents and short-term investments and contract liabilities of $464.4 million related mainly to the Kyowa Kirin agreement. Management believes this cash, combined with expected partnership payments, can fund its operating plan into the fourth quarter of 2027 and through initial Phase 3 ziftomenib readouts anticipated in 2028.
Kura Oncology reported first-quarter 2026 results showing its transition into a commercial-stage company. Total revenue reached $18.3 million, including $5.8 million in net product revenue from KOMZIFTI, its newly launched AML drug, and $12.5 million of collaboration revenue from the Kyowa Kirin partnership.
The company’s operating expenses rose with commercialization and late-stage development, driving a net loss of $73.3 million, or $0.83 per share. Research and development spending was $65.3 million and selling, general and administrative expenses were $31.6 million, reflecting expanding clinical programs and commercial infrastructure.
Kura ended March 31, 2026 with $580.8 million in cash, cash equivalents and short-term investments and contract liabilities of $464.4 million related mainly to the Kyowa Kirin agreement. Management believes this cash, combined with expected partnership payments, can fund its operating plan into the fourth quarter of 2027 and through initial Phase 3 ziftomenib readouts anticipated in 2028.
Kura Oncology reported first quarter 2026 results highlighted by the first commercial sales of KOMZIFTI, its menin inhibitor for relapsed or refractory NPM1‑mutated AML. KOMZIFTI generated $5.8 million in net product revenue, with 85 new patient starts, 157 total prescriptions and more than 93% payer coverage.
Total revenue was $18.3 million, up from $14.1 million a year earlier, driven by new product revenue and $12.5 million of collaboration revenue. Kura posted a net loss of $73.3 million as it increased R&D and commercialization spending. Cash and investments of $580.8 million, plus $180 million in anticipated collaboration payments, are expected to fund its ziftomenib AML program through topline Phase 3 KOMET‑017 results anticipated in 2028.
Kura Oncology reported first quarter 2026 results highlighted by the first commercial sales of KOMZIFTI, its menin inhibitor for relapsed or refractory NPM1‑mutated AML. KOMZIFTI generated $5.8 million in net product revenue, with 85 new patient starts, 157 total prescriptions and more than 93% payer coverage.
Total revenue was $18.3 million, up from $14.1 million a year earlier, driven by new product revenue and $12.5 million of collaboration revenue. Kura posted a net loss of $73.3 million as it increased R&D and commercialization spending. Cash and investments of $580.8 million, plus $180 million in anticipated collaboration payments, are expected to fund its ziftomenib AML program through topline Phase 3 KOMET‑017 results anticipated in 2028.
Vanguard Capital Management reports beneficial ownership of 4,428,812 shares of Kura Oncology common stock, representing 5.01% of the class as of 03/31/2026. The filing shows sole dispositive power over 4,428,812 shares and sole voting power for 643,127 shares. The filing states these holdings include securities held by Vanguard funds and certain affiliates and that no other single person’s interest exceeds 5%.
Kura Oncology has called a virtual 2026 Annual Meeting for June 4, 2026 at 8:30 a.m. Pacific Time to elect three Class III directors and handle key governance votes. Stockholders will vote on ratifying Ernst & Young as auditor, approving executive pay on an advisory basis, and choosing how often to hold future Say-on-Pay votes.
The agenda also includes amendments to the Amended and Restated 2014 Equity Incentive Plan, raising its share reserve to 41,077,686 shares including a 6,500,000‑share increase, and changes to the 2015 Employee Stock Purchase Plan. Only holders of 88,762,704 shares outstanding as of April 6, 2026 may vote, primarily via internet or telephone.
Kura Oncology Inc received an amended Schedule 13G/A filing from The Vanguard Group reporting 0 shares beneficially owned, representing 0% of the class. The filing explains an internal realignment effective January 12, 2026, after which certain Vanguard subsidiaries report ownership separately in reliance on SEC Release No. 34-39538.
The amendment is signed by a Vanguard officer on 03/27/2026 and lists Vanguard's address and that no single other person's interest in the reported securities exceeds 5%.